Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 15/20 | 1.00 |
| ▸ | P2RY4 | P51582 | 10/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.96 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14396709 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL716498 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL5484468 | 0.94 | P2RY2 (0.88) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL2778525 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL76683 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL24414746 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL12671699 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL14976686 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL14406726 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL107380 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| WO-2018035311-A1 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION USING READING FRAME SURVEILLANCE | GRAY JOHN T (US) | 2018-02-22 | — | — | WO | claimed |
| US-20120195936-A1 | RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION | ETHRIS GMBH (DE) | 2012-08-02 | — | — | US | claimed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | claimed |
| US-6184364-B1 | DEHYDRATING URIDINE TO FORM 2,2'-ANHYDROURIDINE, CONVERTING TO UNPROTECTED 2'-AZIDO-2'-DEOXYURIDINE, IODINATING TO FORM 5-IODO-2'-AZIDO, 2'-DEOXYURIDINE, THEN REDUCING TO 5-IODO, 2'-AMINO-2'-DEOXYURIDINE; SELEX LIGANDS | NEXSTAR PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | claimed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | claimed |
| EP-4739714-A1 | SINGLE DOMAIN ANTIBODIES FOR GPRC5D | Overland Therapeutics (US) Inc. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4736958-A2 | ANTI-5T4 ANTIBODIES AND USES THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115317-A1 | GENE THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| US-12599560-B2 | Lipids and lipid nanoparticle formulations | LONGUIDE BIOPHARMA CORPORATION (CN) | 2026-04-14 | — | — | US | disclosed |
| US-12594245-B2 | Dry powder formulations for messenger RNA | TRANSLATE BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0880598-A1 | NUCLEIC ACID ANALYSIS TECHNIQUES | Affymetrix, Inc. (a California Corporation) (US) | 1998-12-02 | — | — | EP | disclosed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | disclosed |
| WO-1997027317-A1 | NUCLEIC ACID ANALYSIS TECHNIQUES | AFFYMETRIX, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599560-B2 | Lipids and lipid nanoparticle formulations | NPC1, NPC1L1, NSUN3 | P2RY2 4697/4885P2RY4 4717/4885P2RY6 4585/4885 |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | SMN1; SMN2, CDR2, ATXN2 | P2RY2 1673/4885P2RY4 2577/4885P2RY6 2994/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY4 4107/4885P2RY6 3298/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY4 4107/4885P2RY6 3298/4885 |
| US-20260115317-A1 | GENE THERAPY | CCL11, MPO, GSTA2 | P2RY2 3535/4885P2RY4 3504/4885P2RY6 2469/4885 |
| US-12594245-B2 | Dry powder formulations for messenger RNA | METTL16, RBM25, RNMT | P2RY2 942/4885P2RY4 3568/4885P2RY6 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.